49 results about "Etiracetam" patented technology

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.

The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.

The invention discloses a new synthesizing technique of chiral drug (S)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide ( left Piracetam) intermediate (S)-(+)-2-aminobutanamide hydrochlorate, which comprises the following steps: adopting 2-brobutyrate as initial raw material; aminating; esterifying; ammonolyzing; detaching; looping; obtaining the object compound; making mixed rotary free alkaline (+-)-2-aminobutanamide; adopting half-quantum resolution method to connect chemical detaching salt to evolve salt; removing the detaching agent through alkalization; obtaining the (S)-(+)-2-aminobutanamidehydrochlorate with optical activity; using the mother liquor to make the product. The invention improves the receiving rate and saves the cost of raw material with simply technical operation and low cost, which resolves the resolved mother liquor after racemic action again to reduce the pollution of environment, therefore fitting for industrialized manufacturing.

The present invention discloses a high dose rapidly dispersing three-dimensional printing dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water in a time period of less than about 10 seconds. Also disclosed are methods of making the dosage forms and methods of treating diseases, conditions or disorders that are therapeutically responsive to levetiracetam. The invention also provides methods for preparing the dosage forms.

The invention discloses a preparation method for a levetiracetam intermediate (S)-alpha-ethyl-2-oxo-1-pyrrolidine acetic acid, which takes (RS)-alpha-ethyl-2-oxo-1- pyrrolidine acetic acid as the starting material and takes (R)-alpha-methyl benzylamine as resolving agent to get the product through resolving in resolving solvent. The invention is characterized in that the resolving solvent can be C1-C7 ketones, C1-C7 alcohols, C1-C4 esters or the mixture of the solvents. In addition, the by-product (R)-alpha-ethyl -2 - oxo -1 - pyrrolidine acetic acid can be recovered through racemization under the effect of alkali so as to regain the (RS)-alpha-ethyl -2-oxo-1- pyrrolidine acetic acid. Compared with the existing invention, the preparation method of the invention has the advantages that during resolving, the solvent selected for the compound (RS)-alpha-ethyl -2-oxo -1 - pyrrolidine acetic acid has high resolving efficiency and small toxicity; the resolving salt only needs to be refined once, so that the optical purity of (S)-alpha-ethyl -2-oxo -1 - pyrrolidine acetic acid can meet the requirement (alpha<20>D is equal to -25.0 plus or minus 1 degree (C is equal to 1, acetone)). In addition, the racemic recovery of the compound (R)-alpha-ethyl -2-oxo-1-pyrrolidine acetic acid can reduce environmental pollution and decrease the cost of the product.

The invention discloses a method for detecting devetiracetam (R-isomer) from levetiracetam injection, and adopts high performance liquid chromatography to carry out qualitative or / and quantitative detection of the R-isomer, The detection condition of liquid chromatography comprises: chromatographic column: cellulose-three (3,5-dichlorophenyl carbamate) silica gel column; Mobile phase: n-hexane, dehydrated alcohol; Wherein, n-hexane (vol.% ): absolute ethanol (vol.%)=90~70: 10~30; the mobile phase adopts isocratic elution. The method of the invention can effectively detect the levetiracetam in the levetiracetam injection, and has specificity and stability indicating ability. Moreover, the levetiracetam injection can be directly diluted and tested without pretreatment of samples, which is convenient and fast; the detection limit of the method of the invention reaches 0.003%, and the quantification limit reaches 0.005%, which is accurate and sensitive.